- Home
- CWEN vs PCVX Comparison
CWEN vs PCVX Comparison
Compare CWEN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- PCVX
- Stock Information
- Founded
- CWEN 2012
- PCVX 2013
- Country
- CWEN United States
- PCVX United States
- Employees
- CWEN N/A
- PCVX N/A
- Industry
- CWEN Electric Utilities: Central
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- CWEN Utilities
- PCVX Health Care
- Exchange
- CWEN Nasdaq
- PCVX Nasdaq
- Market Cap
- CWEN 3.8B
- PCVX 4.0B
- IPO Year
- CWEN 2013
- PCVX 2020
- Fundamental
- Price
- CWEN $35.51
- PCVX $45.43
- Analyst Decision
- CWEN Buy
- PCVX Strong Buy
- Analyst Count
- CWEN 6
- PCVX 7
- Target Price
- CWEN $37.17
- PCVX $101.67
- AVG Volume (30 Days)
- CWEN 1.2M
- PCVX 1.4M
- Earning Date
- CWEN 11-04-2025
- PCVX 11-04-2025
- Dividend Yield
- CWEN 4.98%
- PCVX N/A
- EPS Growth
- CWEN 125.75
- PCVX N/A
- EPS
- CWEN 2.34
- PCVX N/A
- Revenue
- CWEN $1,375,000,000.00
- PCVX N/A
- Revenue This Year
- CWEN $5.03
- PCVX N/A
- Revenue Next Year
- CWEN $13.19
- PCVX N/A
- P/E Ratio
- CWEN $15.19
- PCVX N/A
- Revenue Growth
- CWEN 0.81
- PCVX N/A
- 52 Week Low
- CWEN $24.40
- PCVX $27.66
- 52 Week High
- CWEN $35.75
- PCVX $107.22
- Technical
- Relative Strength Index (RSI)
- CWEN 77.03
- PCVX 61.99
- Support Level
- CWEN $32.08
- PCVX $40.14
- Resistance Level
- CWEN $35.75
- PCVX $45.90
- Average True Range (ATR)
- CWEN 0.89
- PCVX 2.14
- MACD
- CWEN 0.32
- PCVX -0.28
- Stochastic Oscillator
- CWEN 94.65
- PCVX 90.21
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.